The Immunoshift technology developed by VCN scientists has achieved functional deletions on immunodominant T-cell epitopes present in oncolytic adenovirus, which allows a more efficient triggering of anti-tumor immune responses. Of note, these functional T-cell epitopes deletions are not associated with reduced cytotoxicity or reduced viral replication in comparison to a parental adenovirus. Oncolytic adenovirus including  immunoshift technology are able to mount anti-tumor immune responses in a more efficiently  compared to non-modified counterparts, when tested both in a model of tumor-challenge vaccination or  in an established tumor model.